QGEN - Qiagen N.V.
After hours:
| Previous close | 46.48 |
| Open | 46.11 |
| Bid | 44.95 x 800 |
| Ask | 45.88 x 900 |
| Day's range | 45.73 - 46.20 |
| 52-week range | 40.38 - 51.18 |
| Volume | |
| Avg. volume | 825,474 |
| Market cap | 10.469B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 29.06 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Qiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory
QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.
- Zacks
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
- Zacks
Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down
Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.
- Zacks
Qiagen (QGEN) Q1 Earnings Beat Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Simply Wall St.
Is Weakness In Qiagen N.V. (NYSE:QGEN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Qiagen's (NYSE:QGEN) recent performance, when its stock has declined 10...
- Zacks
Will Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Earnings Preview: Qiagen (QGEN) Q1 Earnings Expected to Decline
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
- Zacks
QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.
- Simply Wall St.
With 83% ownership, Qiagen N.V. (NYSE:QGEN) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading...
- Zacks
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
- Zacks
BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
- Simply Wall St.
Investing in Qiagen (NYSE:QGEN) five years ago would have delivered you a 37% gain
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...
- Simply Wall St.
Qiagen Full Year 2022 Earnings: EPS Misses Expectations
Qiagen ( NYSE:QGEN ) Full Year 2022 Results Key Financial Results Revenue: US$2.14b (down 4.9% from FY 2021). Net...
- Zacks
QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down
The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.
- Zacks
Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow
QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.
- Simply Wall St.
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
In this article we are going to estimate the intrinsic value of Qiagen N.V. ( NYSE:QGEN ) by taking the forecast future...
- Zacks
QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails
The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.
- Zacks
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.
- Zacks
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.
